Information Provided By:
Fly News Breaks for July 5, 2018
ALNY
Jul 5, 2018 | 05:08 EDT
The papers in the New England Journal of Medicine reinforce the superior profile for patisiran in hereditary transthyretin-mediated, B. Riley FBR analyst Madhu Kumar tells investors in a research note. The analyst reiterates a Buy rating on the shares with a $200 price target.
News For ALNY From the Last 2 Days
There are no results for your query ALNY